Zentalis Pharmaceuticals Files 8-K Report

Ticker: ZNTL · Form: 8-K · Filed: Apr 9, 2024 · CIK: 1725160

Sentiment: neutral

Topics: sec-filing, 8-k, disclosure

Related Tickers: ZNTL

TL;DR

Zentalis filed an 8-K. Check for updates.

AI Summary

On April 9, 2024, Zentalis Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. No specific financial figures or material events beyond the filing itself are detailed in the provided text.

Why It Matters

This filing indicates Zentalis Pharmaceuticals is providing updates or disclosures to the SEC, which could contain important information for investors.

Risk Assessment

Risk Level: low — The provided text is a standard SEC filing notification and does not contain specific operational or financial risks.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing?

The filing is primarily for Regulation FD Disclosure and to report Financial Statements and Exhibits.

What is the exact date of the earliest event reported in this filing?

The date of the earliest event reported is April 9, 2024.

What is the company's Central Index Key (CIK)?

The company's CIK is 0001725160.

What is Zentalis Pharmaceuticals' Standard Industrial Classification (SIC) code?

Zentalis Pharmaceuticals' SIC code is 2834, which corresponds to Pharmaceutical Preparations.

What is the SEC file number for Zentalis Pharmaceuticals?

The SEC file number for Zentalis Pharmaceuticals is 001-39263.

Filing Stats: 545 words · 2 min read · ~2 pages · Grade level 10.3 · Accepted 2024-04-09 16:30:50

Key Financial Figures

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. Beginning on April 9, 2024, spokespersons of Zentalis Pharmaceuticals, Inc. (the "Company") plan to present the information in the Corporate Presentation furnished as Exhibit 99.1 to this Current Report on Form 8-K (this "Current Report") and incorporated herein by reference at conferences and in meetings with investors and analysts. The information contained in Item 7.01 of this Current Report (including Exhibit 99.1 attached hereto) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly provided by specific reference in such a filing.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits The following Exhibit 99.1 relating to Item 7.01 shall be deemed to be furnished, and not filed: ExhibitNo. Description 99.1 Corporate Presentation, dated April 2024. 104 Cover Page Interactive Data File (embedded within the inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ZENTALIS PHARMACEUTICALS, INC. Date: April 9, 2024 By: /s/ Kimberly Blackwell, M.D. Kimberly Blackwell, M.D. Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing